{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:54:00Z","timestamp":1793084040581,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":527,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) present with diverse left ventricular ejection fraction (LVEF). This study assessed tafamidis efficacy by baseline LVEF in the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and its long-term extension (LTE) study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients were randomized to 30\u2009months of tafamidis or placebo treatment in ATTR-ACT. On completion, patients could join an LTE study to receive tafamidis. All-cause mortality (death, heart transplant, or cardiac mechanical assist device implantation) from baseline to the end of follow-up was assessed in patients continuously treated with tafamidis (80\u2009mg meglumine or 61\u2009mg free acid) or delayed tafamidis treatment (placebo in ATTR-ACT; tafamidis in the LTE study) according to baseline LVEF (&amp;lt;50% or \u226550%). Supportive outcomes were evaluated over a shorter follow-up. Patients with baseline LVEF &amp;lt;50% (n\u2009=\u2009177: 88 tafamidis- and 89 placebo-treated) had signs of more severe heart failure, a higher proportion were Black, and had variant ATTR-CM than those with LVEF \u226550% (n\u2009=\u2009171: 85 tafamidis- and 86 placebo-treated). At the end of follow-up (median 60\u201364\u2009months), all-cause mortality was numerically higher in patients with baseline LVEF &amp;lt;50%; however, consistent with supportive findings, continuous tafamidis treatment was associated with a 47% reduction in mortality risk compared with delayed tafamidis treatment in patients with LVEF &amp;lt;50% and \u226550% (hazard ratio 0.53 [95% confidence interval 0.367\u20130.758]; p\u2009&amp;lt;\u20090.001, and 0.53 [0.344\u20130.818]; p\u2009&amp;lt;\u20090.01, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early initiation of tafamidis is associated with reduced mortality in patients with ATTR-CM, irrespective of initial LVEF value.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: ClinicalTrials.gov \u00a0NCT01994889, NCT02791230.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3330","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T02:43:58Z","timestamp":1719456238000},"page":"2038-2046","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction"],"prefix":"10.1093","volume":"26","author":[{"given":"Brian","family":"Drachman","sequence":"first","affiliation":[{"name":"University of Pennsylvania Health System , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Referral Center for Cardiac Amyloidosis, CHU Henri Mondor , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca S.","family":"Angeli","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Madrid ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"Universidad Francisco de Vitoria (UFV) , Pozuelo de Alarcon ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"2026010913051198200_ejhf3330-bib-0001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: Taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2026010913051198200_ejhf3330-bib-0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913051198200_ejhf3330-bib-0003","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0004","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fca-2022-0096","article-title":"Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A plain language summary","volume":"19","author":"Elliott","year":"2023","journal-title":"Future Cardiol"},{"key":"2026010913051198200_ejhf3330-bib-0006","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: Further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0008","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"},{"key":"2026010913051198200_ejhf3330-bib-0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","article-title":"Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study","volume":"12","author":"Garcia-Pavia","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0010","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913051198200_ejhf3330-bib-0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0012","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0735-1097(03)00789-7","article-title":"The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure","volume":"42","author":"Curtis","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051198200_ejhf3330-bib-0013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026010913051198200_ejhf3330-bib-0014","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: Disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913051198200_ejhf3330-bib-0015","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.0717","article-title":"Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913051198200_ejhf3330-bib-0016","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function","volume":"10","author":"Martyn","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026010913051198200_ejhf3330-bib-0017","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cardfail.2022.10.381","article-title":"Multicenter transthyretin cardiac amyloidosis study demonstrates differences in phenotype and outcomes by race","volume":"29","author":"Cavalier","year":"2023","journal-title":"J Card Fail"},{"key":"2026010913051198200_ejhf3330-bib-0018","author":"Spanish Ministry of Health. Medication information"},{"key":"2026010913051198200_ejhf3330-bib-0019","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: Insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/2038\/65511508\/eurjhf_26_9_2038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/2038\/65511508\/eurjhf_26_9_2038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:08Z","timestamp":1767981968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/9\/2038\/8328665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,6,26]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3330","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"2024-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}